

REGENERON PHARMACEUTICALS INC  
 Form 4  
 May 18, 2010

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**VAGELOS P ROY**

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**REGENERON PHARMACEUTICALS INC [REGN]**

3. Date of Earliest Transaction (Month/Day/Year)  
 05/14/2010

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |         |   |         |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|---------|---|---------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                                      |         |   |         |
| Common Stock                    | 05/14/2010                           |  | S                              |   | 17,400  | D  | \$ 27.19<br><u>(1)</u>                     | 531,351 | D |         |
| Common Stock                    | 05/14/2010                           |  | S                              |   | 2,600   | D  | \$ 26.96<br><u>(2)</u>                     | 528,751 | D |         |
| Common Stock                    | 01/05/2010                           |  | G <sup>(3)</sup>               | V   | 8,595   | D  | \$ 0                                       | 215,127 | I | by CLAT |
| Common Stock                    | 04/12/2010                           |  | G <sup>(3)</sup>               | V   | 7,952   | D  | \$ 0                                       | 207,175 | I | by CLAT |

Stock

|              |        |   |                |
|--------------|--------|---|----------------|
| Common Stock | 2,156  | I | By 401(k) Plan |
| Common Stock | 63,925 | I | by GRAT        |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|

## Reporting Owners

| Reporting Owner Name / Address                                      | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| VAGELOS P ROY<br>777 OLD SAW MILL RIVER ROAD<br>TARRYTOWN, NY 10591 | X             |           |         |       |

## Signatures

By: /s/\*\*Stuart Kolinski For: /s/\*\*P. Roy  
Vagelos 05/18/2010

\_\_\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

The reporting person sold 17,400 shares of Company stock on May 14, 2010 at prices ranging from \$27.10 to \$27.40. Upon request by the Commission staff, the Company, or a security holder of the Company, we will provide full information regarding the number of shares sold by the reporting person on May 14, 2010 at each separate price.

The reporting person sold 2,600 shares of Company stock on May 14, 2010 at prices ranging from \$26.94 to \$26.98. Upon request by the

(2) Commission staff, the Company, or a security holder of the Company, we will provide full information regarding the number of shares sold by the reporting person on May 14, 2010 at each separate price.

(3) Gift of Common Stock to charitable organization.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.